Shigeyuki Toyoizumi
Pfizer R&D Japan
Tokyo, Japan
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.
Journal: Rheumatology and therapy
Published: September 06, 2025
Incidence and Risk of Malignancy in Japanese Patients With Rheumatoid Arthritis in the National Database of Rheumatic Diseases in Japan (NinJa Database).
Journal: International journal of rheumatic diseases
Published: February 14, 2025
Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials.
Journal: Modern rheumatology
Published: September 03, 2024
Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry.
Journal: Rheumatology and therapy
Published: February 22, 2024
Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC-A Brief Report From the CROWN Study.
Journal: JTO clinical and research reports
Published: September 28, 2023
Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib.
Journal: Modern rheumatology
Published: July 18, 2023
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan.
Journal: JTO clinical and research reports
Published: January 04, 2023
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
Journal: Breast cancer (Tokyo, Japan)
Published: April 27, 2022
Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
Journal: Journal of gastroenterology and hepatology
Published: December 16, 2021
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Journal: Investigational new drugs
Published: January 30, 2021
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Journal: Modern rheumatology
Published: November 30, 2018
Last Updated: 09/26/2026